# US 2016/0355477 A1 · Indole carboxamide derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355477 A1
- Document ID: US20160355477A1
- Status: Published application
- Kind: A1
- Application number: 15/242,160
- Filed: 2016-08-19
- Published: 2016-12-08
- Earliest claimed: 2012-09-07
- Assignees: Novartis AG
- Inventors: Jan Jiricek; Ravinder Reddy Kondreddi; Paul William Smith
- Web page: https://patentgrep.com/patent/US20160355477A1

## CPC

- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/06: for tuberculosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R1, R2, R3, R4, R5 and R6 are as defined herein.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A method of treating tuberculosis comprising the step of administering to a human in need thereof a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, and at least one additional pharmaceutical agent, wherein said human has (i) a sputum smear-positive, sputum smear-negative, or extrapulmonary tuberculosis; (ii) tuberculosis caused by drug resistant Mycobacterium tuberculosis complex (M. tuberculosis) organisms; or (iii) tuberculosis combined with human immunodeficiency virus (HIV) infection, and wherein the compound of Formula I is:
wherein
R1 is H or methyl;
R2 is H, methyl, halo, cyano, trifluoromethyl, or methoxy;
R3 is H, methyl, or methoxy;
R4 is H, methyl, halo, cyano, trifluoromethoxy, methoxy, —(O(CH2)m)n-morpholinyl, piperidinyl, ((C1-C4)alkyl)NH—, or (phenyl)NH—, where m is 1 or 2 and n is 0 or 1; or
R3 and R4 taken together with the aromatic carbon atoms to which they are attached form a fused 1,3-dioxolo group;
R5 is H or halo;
provided that R2, R3, R4 and R5 are not all hydrogen;
R6 is
(i) (C4-C6)alkyl, where said (C4-C6)alkyl is optionally substituted with phenyl which is optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy;
(ii) (C5-C7)cycloalkyl, or —CH2—(C5-C7)cycloalkyl, where said (C5-C7)cycloalkyls are optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy, provided that R6 is not an unsubstituted cyclohexyl, when R2 and R4 are both methyl;
(iii) spiral(C8-C11)cycloalkyl; or
(iv) phenyl, where said phenyl is optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy, provided that R6 is not an unsubstituted phenyl, when R2 and R4 are both methyl.

### Claim 23

A compound for use in therapy, wherein the compound is of Formula I:
wherein
R1 is H or methyl;
R2 is H, methyl, halo, cyano, trifluoromethyl, or methoxy;
R3 is H, methyl, or methoxy;
R4 is H, methyl, halo, cyano, trifluoromethyl, methoxy, —(O(CH2)m)n-morpholinyl, piperidinyl, ((C1-C4)alkyl)NH—, or (phenyl)NH—, where m is 1 or 2 and n is 0 or 1; or
R3 and R4 taken together with the aromatic carbon atoms to which they are attached form a fused 1,3-dioxolo group;
R5 is H or halo;
provided that R2, R3, R4 and R5 are not all hydrogen;
R6 is
(i) (C4-C6)alkyl, where said (C4-C6)alkyl is optionally substituted with phenyl which is optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy;
(ii) (C5-C7)cycloalkyl, or —CH2—(C5-C7)cycloalkyl, where said (C5-C7)cycloalkyls are optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy, provided that R6 is not an unsubstituted cyclohexyl, when R2 and R4 are both methyl;
(iii) spiral(C8-C11)cycloalkyl; or
(iv) phenyl, where said phenyl is optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy, provided that R6 is not an unsubstituted phenyl, when R2 and R4 are both methyl:
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

The compound of claim 23 wherein said therapy is for the treatment of a disease, disorder, or syndrome mediated by the transportation of essential molecules in the mmpL3 pathway.

### Claim 25

A method for treating a disease, disorder or syndrome mediated by the transportation of essential molecules in the mmpL3 pathway comprising the step of administering to a patient in need thereof,
(i) a first composition comprising a compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient; and
(ii) a second composition comprising at least one additional pharmaceutical agent and a pharmaceutically acceptable carrier or excipient;
wherein the compound is of Formula I:
wherein
R1 is H or methyl;
R2 is H, methyl, halo, cyano, trifluoromethyl, or methoxy;
R3 is H, methyl, or methoxy;
R4 is H, methyl, halo, cyano, trifluoromethyl, methoxy, —O(CH2)m)n-morpholinyl, piperidinyl, ((C1-C4)alkyl)NH—, or (phenyl)NH—, where m is 1 or 2 and n is 0 or 1; or
R3 and R4 taken together with the aromatic carbon atoms to which they are attached form a fused 1,3-dioxolo group;
R5 is H or halo;
provided that R2, R3, R4 and R5 are not all hydrogen;
R6 is
(i) (C4-C6)alkyl, where said (C4-C6)alkyl is optionally substituted with phenyl which is optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy;
(ii) (C5-C7)cycloalkyl, or —CH2—(C5-C7)cycloalkyl, where said (C5-C7)cycloalkyls are optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy, provided that R6 is not an unsubstituted cyclohexyl, when R2 and R4 are both methyl;
(iii) spiral(C8-C11)cycloalkyl; or
(iv) phenyl, where said phenyl is optionally substituted with one to two substituents each independently selected from (C1-C4)alkyl, fluoro-substituted (C1-C4)alkyl, methoxy, hydroxy(C1-C4)alkyl, methoxy(C1-C4)alkyl, ethynyl, cyano, halo, or hydroxy, provided that R6 is not an unsubstituted phenyl, when R2 and R4 are both methyl.

### Claim 26 (depends on 25)

The method of claim 25 wherein said patient is human.

### Claim 27 (depends on 26)

The method of claim 26 wherein said disease, disorder or syndrome is tuberculosis.

### Claim 28 (depends on 27)

The method of claim 27 wherein said essential molecules is trehalose monomycolate.

### Claim 29 (depends on 26)

The method of claim 26 wherein said human has (i) a sputum smear-positive, sputum smear-negative, or extrapulmonary tuberculosis; (ii) tuberculosis caused by drug resistant Mycobacterium tuberculosis complex (M. tuberculosis) organisms; or (iii) tuberculosis combined with human immunodeficiency virus (HIV) infection.

### Claim 30 (depends on 25)

The method of claim 25, wherein said first and second compositions are administered simultaneously.

### Claim 31 (depends on 25)

The method of claim 25, wherein said first and second compositions are administered sequentially in any order.
